Streptococcus thermophilus NCIMB 41856 ameliorates signs of colitis in an animal model of inflammatory bowel disease
Streptococcus thermophilus NCIMB 41856 ameliorates signs of colitis in an animal model of inflammatory bowel disease
复制标题
DOI：
10.3920/bm2016.0110
复制
发表时间：
2017-01-01
影响因子：
5.4
通讯作者：
Cogan, T. A.
中科院分区：
文献类型：
--
作者：
Bailey, J. R.;Vince, V.;Cogan, T. A.
炎症性肠病（IBD）的治疗主要基于抑制症状，通常具有许多副作用。益生菌在IBD中的试验经常产生令人失望的结果。大多数益生菌是不寻常的，因为它们不需要铁的生长，不像许多细菌居住在肠道。由于出血和口服铁补充剂的使用，IBD肠道富含铁;传统的益生菌将迅速被淘汰。我们已经评估了铁响应嗜热链球菌菌株的潜力，以减少结肠炎的迹象。S的功效。在结肠炎的葡聚糖硫酸钠小鼠模型中评价嗜热菌。给药动物给予1x 10（8）cfu S。每天观察嗜热菌，每天进行临床观察。在终止时，确定疾病的大体和组织病理学体征、细胞浸润、细菌的位置和肠道中的细胞因子表达。S.嗜热菌延迟结肠炎的发作并减少疾病的临床体征，包括体重减轻和胃肠道出血。它减少了细菌移位到结肠组织中。在用S.嗜热菌S.嗜热菌对结肠炎动物或对照动物的大体病理学、组织病理学或细胞因子产生没有影响。我们建议S.嗜热菌促进粘膜屏障功能的维持，其减少细菌移位，从而减少免疫刺激和相关炎症。这允许粘膜愈合，减少胃肠道出血和体重减轻。这可以作为目前IBD治疗的局部作用辅助或替代方法进行研究。
Treatment of inflammatory bowel disease (IBD) is mainly based on suppression of symptoms, often with numerous side effects. Trials of probiotics in IBD have frequently produced disappointing results. The majority of probiotics are unusual, since they do not require iron for growth, unlike many bacteria resident in the intestine. The IBD intestine is iron-rich due to bleeding and use of oral iron supplements; conventional probiotics would be rapidly outcompeted. We have evaluated an iron-responsive Streptococcus thermophilus strain for its potential to reduce signs of colitis. Efficacy of S. thermophilus was evaluated in the dextran sodium sulphate mouse model of colitis. Treated animals were given 1x10(8) cfu S. thermophilus per day and clinical observations were taken daily. At termination, gross and histopathological signs of disease, cellular infiltration, location of bacteria, and cytokine expression in the intestine were determined. S. thermophilus delayed onset of colitis and reduced clinical signs of disease, including bodyweight loss and gastrointestinal bleeding. It reduced bacterial translocation into the colonic tissue. Increased numbers of CD8(+) intraepithelial lymphocytes were seen in control animals treated with S. thermophilus. S. thermophilus had no effect on gross pathology, histopathology or cytokine production in either colitic or control animals. We propose that S. thermophilus promotes maintenance of mucosal barrier function which reduces bacterial translocation, thereby reducing immune stimulation and associated inflammation. This allows mucosal healing, reducing gastrointestinal bleeding and weight loss. This could be studied as a locally-acting adjunct or alternative to current IBD treatments.